Surrozen, Inc. (SRZN)
25.48
-0.27
(-1.05%)
USD |
NASDAQ |
Oct 23, 16:00
25.40
-0.08
(-0.31%)
After-Hours: 20:00
Surrozen EPS Diluted (Quarterly) : -0.4059 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.4059 |
| March 31, 2026 | -11.65 |
| December 31, 2025 | -23.87 |
| September 30, 2025 | -8.359 |
| June 30, 2025 | 2.553 |
| March 31, 2025 | -7.434 |
| December 31, 2024 | -8.596 |
| September 30, 2024 | -0.4442 |
| June 30, 2024 | -7.989 |
| March 31, 2024 | -4.239 |
| December 31, 2023 | -4.320 |
| September 30, 2023 | -5.137 |
| Date | Value |
|---|---|
| June 30, 2023 | -4.682 |
| March 31, 2023 | -7.155 |
| December 31, 2022 | -0.3864 |
| September 30, 2022 | -5.730 |
| June 30, 2022 | -5.977 |
| March 31, 2022 | -3.419 |
| December 31, 2021 | -6.403 |
| September 30, 2021 | -6.004 |
| June 30, 2021 | -10.23 |
| March 31, 2021 | -10.76 |
| December 31, 2020 | -13.61 |
| September 30, 2020 | -7.103 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0762 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 32.04M |
| Revenue (Quarterly) | 5.00M |
| Total Expenses (Quarterly) | -27.04M |
| Enterprise Value | 203.77M |
| Gross Profit Margin (Quarterly) | 98.98% |
| Earnings Yield | -173.8% |
| Normalized Earnings Yield | -97.41 |